Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.
about
Potential of afatinib in the treatment of patients with HER2-positive breast cancerOn the mechanism of action of SJ-172550 in inhibiting the interaction of MDM4 and p53IgE-based Immunotherapy of Cancer -A Comparative Oncology ApproachSynergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell linesReversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteinsA nanomolar-potency small molecule inhibitor of regulator of G-protein signaling proteinsMechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance.HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK.A growing family: adding mutated Erbb4 as a novel cancer targetTargeting the human epidermal growth factor receptor 2 pathway in breast cancer.Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.Personalized therapies in the cancer "omics" eraDesign and evaluation of radiolabeled tracers for tumor imaging.Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors.Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles.Irreversible inhibitors of the epidermal growth factor receptor: thienopyrimidine core with α,β-unsaturated amide side chain.The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice.
P2860
Q26999050-28793FD9-4CF6-4569-B714-E23D312DE78CQ28484086-295D063A-E02F-4B3F-B51F-B9926DF99E34Q28655505-270C6E25-16C4-44D7-B607-B11D57AB8A76Q33822560-669607E4-D11B-4BF8-BCD1-27D8DB4AA0E5Q34128004-AFF523C4-815F-41E6-9043-35AD68EB40B6Q34960765-FD02D808-64E2-417E-B280-D391F1D1AE0CQ35624814-F4CB0960-1862-42EE-960C-FD7AF24346E5Q35886688-22365A1D-2994-4D10-B239-3331BB992B99Q36062442-7DEB2827-591A-4585-B594-0B352EA4AFFDQ37205811-4A3041F8-1338-4AC3-972B-B61870CC6175Q37259707-D5A42238-47A9-4DA4-8F5E-04F8964785B4Q37776547-5959AF57-5CD8-4E90-B60C-87CD4E8DC3DBQ38137253-7A495F24-85C7-4BB8-BFB1-C23B260868B4Q38171330-C72A6FA6-925B-4B3A-84B3-3EB823F4F2A7Q38766833-7ECAED34-EBCB-4351-8689-0DDAC6629DBAQ38985980-731EFAB8-6304-4169-AC1B-8888CA6CE1FAQ39636381-FDF59619-11BE-47CE-85D0-385CCCCD0E0AQ50514234-09268A0A-EFB4-4F98-9BC9-3E7822306F1E
P2860
Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Irreversible pan-ErbB tyrosine ...... status and future directions.
@en
Irreversible pan-ErbB tyrosine ...... status and future directions.
@nl
type
label
Irreversible pan-ErbB tyrosine ...... status and future directions.
@en
Irreversible pan-ErbB tyrosine ...... status and future directions.
@nl
prefLabel
Irreversible pan-ErbB tyrosine ...... status and future directions.
@en
Irreversible pan-ErbB tyrosine ...... status and future directions.
@nl
P1476
Irreversible pan-ErbB tyrosine ...... t status and future directions
@en
P2093
Alberto Ocaña
Eitan Amir
P304
P356
10.1016/J.CTRV.2009.08.001
P577
2009-09-04T00:00:00Z